Browse the evidence

Among GLP-1/GIP agonists used in Type 1 Diabetes, tirzepatide produces significantly greater weight loss (10.9%) compared to semaglutide (9.9%) and liraglutide (7.1%).

If you have Type 1 Diabetes and obesity, tirzepatide appears to offer the highest weight loss potential (approx. 11%) compared to semaglutide (approx. 10%) and liraglutide (approx. 7%) over 12 months, though all are effective.

GLP-1/GIP agonists reduce daily insulin requirements in Type 1 Diabetes patients by 8.3 to 11.4 units per day over 12 months, likely due to reduced insulin resistance.

Starting GLP-1/GIP agonists in T1D allows you to lower your daily insulin dose by approximately 8-11 units, which may help manage weight and insulin resistance without increasing hypoglycemia risk.

Self-reported increases in sweet and salty taste perception during GLP-1 or dual GIP/GLP-1 receptor agonist therapy are significantly associated with increased satiety, reduced appetite, and reduced food craving.

If you are taking a GLP-1 medication and notice your taste has changed (e.g., sweets taste stronger or saltier), this is a common and potentially helpful side effect. The research suggests these sensory changes are linked to feeling fuller faster and having fewer cravings, which supports your weight loss efforts. Do not be alarmed by these changes; they may be part of how the medication helps regulate your appetite.

Reducing the dosing frequency of GLP-1 receptor agonists (semaglutide and tirzepatide) after initial weight loss maintenance preserves a significant proportion of weight loss efficacy compared to once-weekly dosing, making it a viable strategy for long-term weight maintenance.

If you are maintaining weight loss on a GLP-1 agonist (like semaglutide or tirzepatide) and face supply issues or high costs, discuss extending the dosing interval with your provider. Instead of stopping completely, moving from weekly to every 10-14 days (or even 28 days for some) can maintain a significant portion of your weight loss (e.g., 50-70%) while saving money and extending supply. This is not a substitute for lifestyle changes but a viable maintenance strategy.

GLP-1 receptor agonists (semaglutide, liraglutide) reduce binge eating episodes and food cravings in Binge Eating Disorder by modulating mesolimbic dopamine signaling and hypothalamic satiety pathways.

If you struggle with binge eating, current talk therapies may not be enough for long-term control. GLP-1 medications like semaglutide or liraglutide are showing promise in reducing the compulsive drive to binge by targeting brain reward circuits. While not yet a standard cure, they offer a biological lever to complement therapy. Discuss with a doctor if you have BED, as small trials show significant symptom reduction.

In patients with type 2 diabetes, subcutaneous semaglutide produces superior long-term weight loss compared to oral semaglutide over a two-year period.

If you have Type 2 Diabetes and are using semaglutide for weight loss, the injection form is significantly more effective than the pill form over the long term (2 years). You will likely lose more weight and have a higher chance of losing 10% or more of your body weight with the injection. However, if you are over 65, the oral pill might offer weight loss results similar to the injection, making it a viable alternative if you want to avoid needles.

Semaglutide 2.4 mg facilitates substantial, sustainable weight loss and improves cardiometabolic health by reducing 'food noise' and maladaptive eating behaviors.

Semaglutide 2.4 mg is an effective tool for reducing 'food noise' and enabling sustainable weight loss when lifestyle changes alone are insufficient. It works by altering hormonal signals related to appetite and satiety.

GLP-1RAs reduce emotional eating in the short term (3-6 months) by modulating reward processing, but this effect may not be long-lasting (12 months) and does not address underlying emotion regulation deficits.

GLP-1RAs like semaglutide can help reduce emotional eating for the first 3-6 months by changing how your brain responds to food rewards. However, this effect may fade after a year, and the medication does not fix the underlying emotional regulation skills. For lasting results, combine GLP-1RA treatment with emotion regulation therapies like CBT or DBT.

GLP-1 receptor agonists (e.g., semaglutide) and dual/triple agonists (e.g., tirzepatide) cause significant lean body mass loss (up to 40% of total weight loss), but this largely reflects reductions in non-contractile organs (liver, kidneys) rather than true skeletal muscle atrophy, with functional strength often preserved or improved.

If you are taking a GLP-1 drug like semaglutide, expect your total 'lean mass' number to drop significantly (up to 40% of weight lost). However, this is mostly water and organ mass (liver/kidneys), not your actual muscle fibers. Your strength likely stays the same or gets better because you are lighter. Focus on resistance training to maintain muscle quality, but do not panic about 'muscle wasting' as the primary driver of weight loss.

Personalized nutrition improves postprandial glycemic response (PPGR) compared to control diets, with a median mean difference of -14.85 mg/dLxh.

Personalized nutrition significantly improves postprandial glycemic response (PPGR) compared to standard diets. This means blood sugar spikes after meals are better managed with personalized advice.

GLP-1 agonist use (specifically semaglutide) is associated with a reduction in body mass index (from 34.1 ± 9 to 30.6 ± 6) and a decrease in smoking frequency/amount (by 14.4%) among users in Saudi Arabia.

If you are using GLP-1 agonists like semaglutide for weight loss, this study suggests you may also see a reduction in smoking frequency. However, be aware that cost and side effects are major reasons people stop taking the medication. To maintain weight loss, consistent use and healthy lifestyle habits (diet and exercise) are crucial, as obesity is a chronic condition requiring long-term management.

Semaglutide treatment is associated with a 26% lower risk of fractures compared to sleeve gastrectomy in adults with obesity.

If you are at high risk for fractures (e.g., older age, diabetes, history of falls) and need to lose weight, discuss semaglutide with your provider. This study suggests it may be safer for your bones than sleeve gastrectomy, offering a 26% lower fracture risk in a large real-world cohort. However, because this is observational data, ensure you monitor your bone health and nutrition regardless of the chosen path.

Enobosarm (3-6 mg/day) preserves total lean mass and reduces fat mass loss when co-administered with semaglutide for weight loss in older adults with overweight/obesity, without compromising overall body weight reduction.

If you are taking semaglutide for weight loss and are concerned about losing muscle, ask your doctor about adding enobosarm (3-6 mg daily). Recent Phase 2b data suggests this combination preserves lean mass and increases fat loss compared to semaglutide alone, without changing total weight loss. Note that this specific combination is still under regulatory review and not yet approved.

GLP-1 receptor agonists (Liraglutide and Semaglutide) promote weight loss and modulate gut microbiota towards a lean-related profile, although clinical data on their specific impact on gut microbiota composition is currently limited.

GLP-1 agonists like Liraglutide and Semaglutide are effective pharmacological treatments for obesity, producing significant weight loss (approx. 6-8%) when combined with lifestyle changes. While they show promise in improving gut microbiota in animal studies, clinical data on these specific changes is still emerging.

In patients with overweight/obesity and established atherosclerotic cardiovascular disease (ASCVD), treatment with semaglutide 2.4 mg significantly reduces total annual medical costs and inpatient healthcare resource utilization compared to non-treated controls.

For patients with obesity and heart disease, using semaglutide 2.4 mg is associated with lower total medical bills over a year, primarily because it reduces the need for hospital stays. This suggests the drug can be cost-effective for this specific population by preventing expensive cardiovascular events.

GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) induce significant weight loss and modify inflammatory markers, suggesting potential oncological benefit, but high-quality data on cancer incidence is currently lacking.

GLP-1 agonists are effective for weight loss and may reduce cancer risk, but long-term cancer data is not yet available. They are a viable option for those who cannot undergo surgery.

GLP-1 receptor agonists (GLP-1RAs) are perceived by patients as effective for weight loss and appetite reduction, with positive treatment experiences correlating with therapy duration of 6 months or longer.

If you are considering GLP-1 medication, know that most patients report significant benefits for weight and appetite, especially if they stay on it for at least 6 months. Be prepared to discuss insurance coverage and side effects openly with your doctor to overcome common barriers.

48 weeks of tirzepatide treatment significantly improves liver steatosis, liver enzymes, and surrogate markers of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM).

For patients with both fatty liver disease and type 2 diabetes, tirzepatide is a well-tolerated treatment that significantly reduces liver fat, improves liver enzyme levels, and slows down fibrosis markers over 48 weeks. While gastrointestinal side effects like nausea are common, they are typically mild and do not force most patients to stop the medication. The benefits extend beyond just weight loss, likely due to the specific dual-action mechanism of the drug on liver metabolism.

Lanifibranor (800-1200 mg daily) significantly improves MASH resolution and fibrosis regression in patients with noncirrhotic MASH compared to placebo.

Lanifibranor (800-1200mg daily) is a promising late-stage drug for MASH that targets multiple metabolic pathways. It significantly improves liver health scores compared to placebo, though monitor for mild weight gain and GI issues.

Saroglitazar (4 mg daily) significantly improves liver enzymes and liver fat content in patients with MASLD/MASH.

Saroglitazar (4mg daily) is approved in India for MASH. It significantly lowers liver enzymes and liver fat. It is currently in Phase 2b trials in the US and other regions.

Tirzepatide therapy significantly improves metabolic control (HbA1c, fasting glucose) and lipid profiles (LDL, HDL, triglycerides) in patients with heart failure.

If you have heart failure and are prescribed tirzepatide, you may see significant improvements in your blood sugar control and lipid profile within six months. This includes lower HbA1c, LDL cholesterol, and triglycerides, and higher HDL cholesterol. These improvements contribute to better long-term cardiovascular health. Discuss these potential benefits with your healthcare provider.

Moderate (~10%) weight loss achieved through diet and exercise reduces pro-inflammatory M1-like macrophages in abdominal subcutaneous adipose tissue (SAT) in adults with adult-onset obesity (AO), but fails to alter these immune cell profiles in those with childhood-onset obesity (CO).

If you developed obesity as an adult, moderate weight loss (around 10%) through diet and exercise may help reduce inflammation in your abdominal fat. However, if you have been obese since childhood, the same level of weight loss might not change the inflammatory state of your fat tissue, even if you lose weight and improve blood markers like insulin. This suggests that long-term obesity history creates a 'memory' in fat tissue that is harder to reverse with standard lifestyle changes alone.

Moderate weight loss increases CD3+CD4+ T cells in both abdominal and femoral subcutaneous adipose tissue in adults with adult-onset obesity (AO), but not in those with childhood-onset obesity (CO).

If you developed obesity as an adult, moderate weight loss may trigger an increase in CD4+ T cells in your fat tissue, which could include regulatory T cells that help manage inflammation. If you have been obese since childhood, this specific immune shift may not occur with the same degree of weight loss. This highlights that long-term obesity history creates a 'memory' in fat tissue that is harder to reverse with standard lifestyle changes alone.

High-volume static stretching improves glycemic control (post-prandial glucose and HbA1c) in individuals with Type 2 Diabetes, potentially by increasing GLUT-4 translocation via AMPK and CaMK pathways.

If you have Type 2 Diabetes, incorporating static stretching into your routine may help lower blood sugar levels, especially after meals. It works by helping your muscles take up glucose without needing as much insulin. It is not a replacement for medication but a helpful addition.